Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR+/HER2– Advanced/Metastatic Breast Cancer

Wood, Robert; Mitra, Debanjali; Courcy, J. De; Iyer, Shrividya

doi:10.1016/j.clinthera.2017.07.009

Cited by 23 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary study endpoint was to describe the health-utility score for the whole cohort. Previous studies on real-world QoL within breast cancer patients found several patient-, disease-, and treatment factors to exert a significant influence on the experienced QoL, including age [19,20], comorbidities [20], type of therapy [19][20][21][22][23][24], number of lines of therapy [21,24], location of metastases, [21,22,25], and disease progression [23,[26][27][28]. Therefor, our secondary endpoints included differences in QoL between subgroups of patients based on age (≥ 65 versus < 65 years), comorbidity according to the Charlson index (yes versus no and multiple subdivisions in comorbidity), tumor subtype (hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) status), current treatment type (endocrine, chemo-and/or targeted therapy), total number of prior palliative treatment lines, and number and metastatic site(s).…”

Section: Study Endpoints and Statistical Analysesmentioning

confidence: 99%

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry

et al. 2020

View full text Add to dashboard Cite

Purpose We aimed to evaluate quality of life (QoL) using the European Quality of Life Five-Dimensions questionnaire (EQ-5D-3L) in a real-world cohort of Dutch advanced breast cancer (ABC) patients. Secondary, we reported differences in QoL between subgroups of patients based on age, comorbidity, tumor-, and treatment characteristics, and assessed the association of duration of metastatic disease and time to death with QoL. Methods ABC patients who attended the outpatient clinic between October 2010 and May 2011 were asked to fill out the EQ-5D-3L questionnaire. Patient-, disease-, and treatment characteristics were obtained from the medical files. Health-utility scores were calculated. Subgroups were described and compared for utility scores by parametric and non-parametric methods. Results A total of 92 patients were included with a median utility score of 0.691 (Interquartile range [IQR] 0.244). Patients ≥ 65 years had significantly worse median utility scores than younger patients; 0.638 versus 0.743, respectively (p = 0.017). Moreover, scores were significantly worse for patients with versus those without comorbidity (medians 0.620 versus 0.725, p = 0.005). Utility scores did not significantly differ between subgroups of tumor type, type of systemic treatment, number of previous palliative treatment(s), or number or location of metastatic site(s). The remaining survival was correlated with utility scores (correlation coefficient (r) = 0.260, p = 0.0252), especially in the subgroup < 65 years (r = 0.340, p = 0.0169), whereas there was no significant correlation with time since metastatic diagnosis (r = − 0.106, p = 0.3136). Conclusion Within this real-world cross-sectional study, QoL was significantly associated with age, comorbidity, and remaining survival duration. The observation of a lower QoL in ABC patients, possibly indicating the last period of life, may assist clinical decision-making on timing of cessation of systemic antitumor therapy.

show abstract

Section: Study Endpoints and Statistical Analysesmentioning

confidence: 99%

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the setting of MBC, QoL is an objective whose importance is secondary only to OS prolongation; it is a complex parameter, whose Baseline After 9 cycles measure relies on definite scales and whose determinants can be deeply subjective [19]. Nevertheless, an effective disease control is the fundamental requirement of a good QoL; in this case series, an extensive regression of metastases in the liver, skin (case 2), and lung (case 4) translated into an evident improvement of patient's QoL, whose daily activities and life satisfaction were ameliorated.…”

Section: Discussionmentioning

confidence: 99%

Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports

et al. 2018

View full text Add to dashboard Cite

Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic chemotherapy, endocrine- or human epidermal growth factor receptor 2 (HER2)-targeted therapy, and palliative therapy. However, no standard approach has been clearly identified for second and further chemotherapy lines in MBC patients. In the phase III clinical trial EMBRACE, eribulin was particularly effective in reducing liver lesions and improving both overall survival and progression-free survival in liver MBC patients. In this series, we collected 8 case reports of Italian clinical practice in which eribulin has shown significant efficacy in reducing liver metastases in MBC patients: complete response was reported in 2 patients, and 4 patients achieved partial response. The treatment was well tolerated, thus confirming that eribulin is a suitable therapeutic option for elderly patients and for those who have metastatic HER2-negative disease. In the setting of MBC, the sequencing of therapeutic agents should consider expected response, side effects, tumor characteristics, and patient’s preferences, in order to successfully tailor the most appropriate therapy beyond earlier lines.

show abstract

“…In MBC patients with hormone-receptor-positive and human epidermal growth factor receptor 2-negative disease, there is significant value in delaying the initiation of chemotherapy due to the associated side effects and their negative impact on HRQoL [20,21]. Decision makers in England and Germany have acknowledged the need for new MBC treatments that are effective and have lower toxicity than chemotherapy and that can thus be used in place of chemotherapy [22,23].…”

Section: Value Of Delayed Chemotherapymentioning

confidence: 99%

A multi-stakeholder approach in optimising patients’ needs in the benefit assessment process of new metastatic breast cancer treatments

et al. 2020

View full text Add to dashboard Cite

There is a growing understanding as science evolves that different cancer types require different approaches to treatment evaluation, especially in the metastatic stages. The introduction of new metastatic breast cancer (MBC) treatments may be hindered by several elements, including the availability of relevant evidence related to disease-specific outcomes, the benefit assessment process around the evaluation of the clinical benefit and the patients' need of new treatments. The Steering Committee (SC) found that not all issues relevant to MBC patients are consistently considered in the current benefit assessment process of new treatments. Among these are overall survival, time-to-event endpoints (e.g. progression-free survival), patients' priorities, burden of disease, MBC-specific quality of life, value in delaying chemotherapy, route of administration, side effects and toxicities, treatment adherence and the benefit of real-world evidence. This paper calls on decision makers to (1) Include MBC-specific patient priorities and outcomes in the overall benefit assessments of new MBC treatments; (2) Enhance multi-stakeholder collaboration in order to improve MBC patient outcomes.

show abstract

Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR+/HER2– Advanced/Metastatic Breast Cancer

Cited by 23 publications

References 23 publications

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry

Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports

A multi-stakeholder approach in optimising patients’ needs in the benefit assessment process of new metastatic breast cancer treatments

Contact Info

Product

Resources

About